

# Publication of the 3<sup>rd</sup> Letter to the shareholders

Chenôve, France, July 31<sup>th</sup> 2015, 15h30 - CROSSJECT (ISIN: FR0011716265 ; Mnemo: ALCJ), the creator of ZENEO®, the world most advanced needle-free injection system, announces the publication of its 3<sup>rd</sup> Letter to shareholders.

This new issue allows readers to discover the latest developments of our supgeneric products portfolio, with a focus on ZENEO® Sumatriptan and ZENEO® L15. The letter also deals with the strengthening of Crossject's IP through the filing of five new patents, and with the positive feedbacks that the company received in the United States.

The 3<sup>rd</sup> Shareholders Letter is available on the website: [www.crossject.com](http://www.crossject.com) (Media / Newsletter).

Follow us on Twitter @Crossject\_.

Next publication: 10 September, 2015 after market closure: Financial results for the 1<sup>st</sup> semester 2015

## Contacts

### Crossject

Patrick Alexandre / Timothée Muller  
info@crossject.com

### Citigate Dewe Rogerson

Laurence Bault /Lucie Larguier  
+33 (0)1 53 32 84 78 / 84 75  
laurence.bault@citigate.fr  
lucie.larguier@citigate.fr

## About CROSSJECT • [www.crossject.com](http://www.crossject.com)

Crossject is using its world-leading needle-free injection system, ZENEO™ to develop an attractive pipeline of high value SUPERGENERICS. These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort.

Crossject's needle-free, pre-filled, single-use ZENEO™ injection systems are unique in that they can be tailored to deliver drugs intradermally, subcutaneously and intramuscularly. This means that ZENEO™ can allow a wide range of drugs and vaccines for a broad range of indications to be developed and approved in a very short period of time. Outside its own portfolio of SUPERGENERICS, Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

CROSSJECT is listed on Alternext Paris (Mnemo: ALCJ, ISIN: FR0011716265).

## Disclaimer

This document can contain information of an estimated nature. This information constitutes either trends or objectives and couldn't be regarded as provisions of a result or any other performance indicator. This information is submitted in a nature of risks and uncertainties, which are in certain cases out of control of the company, especially in the context of a R&D process. A more detailed description of these risks and uncertainties appears in the company's registration document, available on their website ([www.crossject.com](http://www.crossject.com)).